Key Takeaways

• NAVIFY® Oncology Hub, designed and developed by Roche Pharmaceuticals, was designed to streamline the clinical workflows of oncologists and reduce the administrative burden on clinicians.
•  Navista™ TS was designed to assist oncologists in improving outcomes and reduce costs associated with patient treatment as they switch to value-based care.
• The Nuance Dragon Medical One solution is a cloud-based, AI-powered solution that uses speech recognition to assist oncologists to quickly and accurately gather cancer data towards improving cancer research and treatment.

Introduction

1. NAVIFY® Oncology Hub

 

Source

 

• NAVIFY® Oncology Hub was designed and developed by Roche Pharmaceuticals. While Roche is headquartered in Switzerland, they have a presence in the U.S. 
• In December 2021, the company announced the launch of this product which serves to provide a "central workspace for clinicians to quickly access relevant patient data to optimize care decisions and enhance care coordination."
• This product serves as a central place for patient data and insights. It helps to inform the day-to-day care decisions of clinicians by:
• Aggregating relevant data from all disparate healthcare IT systems.
• Organizing fragmented data into actionable and meaningful insights.
• Contextualizing and displaying multimodal data in the form of an intuitive, longitudinal view of the patient’s journey.
• By streamlining the clinical workflows of oncologists, NAVIFY Oncology Hub helps to reduce the administrative burden on clinicians. This means that oncologists are allowed to spend less time on patient records and dedicate more time to providing care to patients.
• Speaking on the capabilities of the solution, Moritz Hartmann - Global Head of Roche Information Solutions - said: "Clinicians are under enormous pressure to navigate complex workflows and consider all the relevant information to decide on the best possible care option for each patient in a timely fashion. With our digital solutions, we can empower healthcare professionals and patients to make personalized, insights-based decisions across the patient care continuum - helping improve outcomes, and reduce costs to society."
• No success metric for this solution is publicly available. This is likely because this is still a new initiative from Roche Pharmaceuticals having been launched in December 2021. Therefore, data on the effectiveness of the product or customer success stories for this solution has not been compiled or made public.

2. Navista™ Tech Solutions (TS)

 

Source

 

• In April 2021, Cardinal Health announced the launch of the Navista™ TS. This product was designed to assist oncologists in improving outcomes and reduce costs associated with patient treatment as they switch to value-based care.
• The product is made of connected, point-of-service technology solutions including:
• Episode Analytics.
• CureMD Oncology Cloud.
• CORE™, by Jvion - an AI-enabled population health decision support.
• VIPER™, by Deep Lens - a clinical trial matching solution.

• The Navista TS solution helps save time for oncologists by automating manual processes and reducing administrative burdens.

• Speaking on the launch of this technological solution, Heidi Hunter - President of Cardinal Health Specialty Solutions - said: "Community-based oncology practices are facing unprecedented pressure as they pivot to adapt to value-based reimbursement models. With Navista™ TS, we are delivering the most complete set of integrated, AI-enabled solutions and actionable insights to enable oncologists to improve patient care and enhance practice performance."
• Also, no success metric was found for this solution. This is also likely to be because this solution is new as it was launched in 2021. Therefore, data on the effectiveness of the product or customer success stories for this solution has not been compiled or made public.

3. Nuance Dragon Medical One

 

Source

 

 

Source

 

• In August 2020, MITRE and Nuance Communications, Inc. partnered to launch the Nuance Dragon Medical One product. The product was developed to help reduce the burden of work on clinicians and enhance the quality of available cancer data.
• The Nuance Dragon Medical One solution is a cloud-based, AI-powered solution that uses speech recognition to assist oncologists to quickly and accurately gather cancer data towards improving cancer research and treatment.
• The product is configured to incorporate mCODE™ (minimal Common Oncology Data Elements) data elements.
• This solution allows clinicians to directly input vital cancer data into electronic health records (EHRs) using their voice. This improves the quality of documentation, reduces data entry burden, and saves time for oncologists.
• Speaking at the launch of this solution, Diana Nole - Executive Vice President and General Manager of Nuance Communications - said: "Collecting clinical data specific to oncology treatment has traditionally been a difficult task to overcome. Combining Nuance's AI expertise with the mCODE data standard provides oncologists with the ability to easily collect and gain access to critical outcome data by simply using their voice to securely dictate notes and search within the EHR using Nuance Dragon Medical One. This will garner significant advancements in data collection, which will, in turn, dramatically improve patient treatment and care."
• According to a testimonial by Edward-Elmhurst Health, the adoption of this solution helped them save hundreds of hours on clinical documentation and allows physicians to spend more time with patients.
• Furthermore, General Practitioner (GP) noted that the deployment of this solution helped ease pressure on staff and admin is managed within working hours.

Research Strategy